The China Dependence Big Pharma Doesn’t Want Washington to See
U.S. drugmakers are rapidly shifting the front end of America’s pharmaceutical ecosystem (e.g. discovery, early-stage-development, and the IP engine) to China through a surge of licensing deals and cross-border partnerships.